Prosecution Insights
Last updated: July 17, 2026
Application No. 18/021,832

SALT FORM AND CRYSTAL FORM THEREOF OF SULFONYLUREA RING SUBSTITUTED COMPOUND

Final Rejection §102§112
Filed
Feb 17, 2023
Priority
Oct 12, 2022 — CN 202211246849.8 +1 more
Examiner
WARD, PAUL V
Art Unit
1622
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Suzhou Erye Pharmaceutical Co. Ltd.
OA Round
2 (Final)
83%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
72%
With Interview

Examiner Intelligence

Grants 83% — above average
83%
Career Allowance Rate
1408 granted / 1692 resolved
+23.2% vs TC avg
Minimal -12% lift
Without
With
+-11.5%
Interview Lift
resolved cases with interview
Typical timeline
2y 4m
Avg Prosecution
36 currently pending
Career history
1716
Total Applications
across all art units

Statute-Specific Performance

§101
0.7%
-39.3% vs TC avg
§103
29.6%
-10.4% vs TC avg
§102
8.5%
-31.5% vs TC avg
§112
42.9%
+2.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1692 resolved cases

Office Action

§102 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION STATUS OF THE CLAIMS: Claims 1-17 are pending in this application. Claims 2-17 are allowed. Claim 1 is anticipated and obvious, and the rejection of claim 1 under 35 U.S.C. 102 and 103 are maintained for the reasons of record as set forth today, herein below, and in the Office Action dated November 26, 2025 Response to Amendment & Arguments regarding Claim Rejections - 35 USC § 112, first paragraph Applicant’s arguments, filed November 26, 2025, with respect to 35 USC § 112, first paragraph, have been fully considered and are persuasive. The rejections of claims 18-19 has been withdrawn. Response to Arguments regarding Claim Rejections - 35 USC § 102 and 103 Applicant's arguments filed November 26, 2025 have been fully considered but they are not persuasive. MPEP 2112 states: “SOMETHING WHICH IS OLD DOES NOT BECOME PATENTABLE UPON THE DISCOVERY OF A NEW PROPERTY.” The claiming of a new use, new function or unknown property, which is inherently present in the prior art does not necessarily make the claim patentable. In re Best, 562 F.2d 1252, 1254, 195 USPQ 430, 433 (CCPA 1977)”. In this case, the “unknown property” is the salt form structure. This is unknown because the reference is silent on this property (i.e., phosphoric sodium salt). MPEP further states: “A REJECTION UNDER 35 U.S.C. 102/103 CAN BE MADE WHEN THE PRIOR ART PRODUCT SEEMS TO BE IDENTICAL EXCEPT THAT THE PRIOR ART IS SILENT AS TO AN INHERENT CHARACTERISTIC. Where Applicant claims a composition in terms of a function, property or characteristic and the composition of the prior art is the same as that of the claim but the function is not explicitly disclosed by the reference, the Examiner may make a rejection under both 35 U.S.C. 102 and 103, expressed as a 102/103 rejection.” Again, the “CHARACTERISTIC”, which the prior art is silent is the crystalline salt form. This is not an ordinary inherency situation where is it is not explicitly stated what the product actually is. Here the reference explicitly teaches exactly what the compound is. The only difference is a characteristic about which the reference happens to be silent. See also Ex parte Anderson, 21 USPQ 2nd 1241 at 1251, discussion of Rejection E. There, the decision states, “There is ample precedent for shifting the burden to an applicant to reproduce a prior art product whose final structure or properties are, at least, in part determined by the precise process used in its manufacture.” (See page 1253). The “properties” branch of that statement applies here. Applicants are reminded that the USPTO has no testing facilities. If Applicants’ reasoning were accepted, then any anticipation rejection of an old compound could always be overcome by tacking on some characteristic or property which the reference was silent, regardless of whether the prior art material was any different from the claimed material. For example, if it did not happen to mention the color, one could patent an old compound just by adding “which is green” or “which is not indigo”. One could put in a limitation about density (e.g., density is not 1.4”), melting point, refractive index, solubility, and etc., and then simply point to the silence of the reference, as Applicants have done here. Or one could add properties like or “does not explode on tapping” or “in the form of micro-needles”. Thus, the rejection of claim 1 under 35 U.S.C. 102, set forth in the Office action dated October 19, 2016 and today has been maintained for the reasons of record for the reasons set forth herein. Allowable Subject Matter Claims 2-17 are allowed. The crystalline compounds comprising XRPD patterns were not found to be obvious or anticipated by the prior art of record. The prior art does not teach or suggest the crystalline compounds in the manner claimed by the Applicant comprising the XRPD patterns, thermogravimetric analysis curves , endothermic peaks, and differential scanning calorimetric curves. Therefore, these claims are allowed. Examiner Notes Examiner suggests to Applicant to schedule an Examiner Interview to discuss the rejection herein above, and possibly place all of the claims in condition for allowance. Conclusion Claims 1-17 are pending. Claim 1 is rejected. Claims 2-17 are allowed. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to PAUL V WARD whose telephone number is (571)272-2909. The examiner can normally be reached M-F 9am to 5pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, James Alstrum-Acevedo can be reached at 571-272-5548. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /PAUL V WARD/ Primary Examiner, Art Unit 1622
Read full office action

Prosecution Timeline

Feb 17, 2023
Application Filed
Nov 26, 2025
Non-Final Rejection mailed — §102, §112
Feb 12, 2026
Response Filed
Jun 24, 2026
Final Rejection mailed — §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12678384
SANITIZING COMPOSITIONS CONTAINING IONIC LIQUID
3y 6m to grant Granted Jul 14, 2026
Patent 12679810
METHOD FOR THE PREPARATION OF SULFINPYRAZONE
3y 3m to grant Granted Jul 14, 2026
Patent 12673057
RIPK2 INHIBITION FOR THE TREATMENT OF CANCER
3y 9m to grant Granted Jul 07, 2026
Patent 12661432
MULTIFUNCTIONAL, HYDROGEL HYBRID MATERIAL, THE METHOD OF ITS PREPARATION AND THE USE IN THE TREATMENT OF BONE LOSSES
3y 3m to grant Granted Jun 23, 2026
Patent 12655141
INHIBITORS OF NOTCH SIGNALING PATHWAY AND USE THEREOF IN TREATMENT OF CANCERS
4y 8m to grant Granted Jun 16, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
83%
Grant Probability
72%
With Interview (-11.5%)
2y 4m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1692 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month